FDA Issues Safety Warning on Lunesta
The Carlat Psychiatry Report, Volume 12, Number 6, June 2014
https://www.thecarlatreport.com/newsletter-issue/tcprv12n6/
Issue Links: Learning Objectives | Editorial Information
Topics: News of Note
In mid-May, the FDA released a warning that eszopiclone (Lunesta) can cause next-day impairment when taken at the recommended target dose of 3 mg/day. As a result, the FDA has lowered the recommended starting dose to 1 mg/day.
You can't view details of this content, please login or buy subscription here